Clinical Trial Update: A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 study on tezepelumab for atopic dermatitis was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Tezepelumab (tezepelumab)

Snippet

Sponsor: Amgen | Conditions: Atopic Dermatitis | Phase 2 | Status: TERMINATED | Results posted: 2022-03-10